Description
Latin name
Gastal
release form
resorption tablets
packaging 24 pcs
Pharmacological action
Pharmacological group: antacid
ATX code: A02AX
Pharmacological properties
Pharmacodynamics. Gastal ® – a combined antacid, the accumulation of epidermal growth factor at the site of damage to the mucous membrane, increasing the concentration of phospholipids in the walls of the stomach.
Pharmacokinetics. Gastal ® does not have a systemic effect in patients with normal renal function. After interacting with hydrochloric acid of gastric aluminum juice, the hydroxide reacts with phosphates and carbonates in the alkaline environment of the intestine and is excreted in the feces in the form of insoluble salts. Magnesium hydroxide reacts with hydrochloric acid in the gastric juice to form magnesium chloride, which has osmotic properties and a mild laxative effect, which neutralizes the fixing effect of aluminum hydroxide in the small intestine. Magnesium ions are excreted in the feces as an insoluble carbonate.
Indications
Dyspeptic symptoms such as discomfort or pain in the epigastrium, heartburn, sour belching after errors in diet, excessive consumption of ethanol, coffee, nicotine, etc.
dyspeptic symptoms, such as discomfort or pain in the epigastrium, heartburn, sour belching (and their prevention), resulting from the use of certain drugs (non-steroidal anti-inflammatory drugs, glucocorticosteroids, etc.)
conditions accompanied by increased acid formation: peptic ulcer gastritis, reflux esophagitis hernia of the esophageal opening of the diaphragm.
Contraindications
Hypersensitivity to aluminum salts, magnesium or other components of the drug severe renal failure Alzheimer’s disease hypophosphatemia lactose intolerance, lactase deficiency or glucose-galactose malabsorption children under 6 years of age.
Caution
In case of chronic renal failure (CRF), pregnancy and breastfeeding, adults and children over 12 years old with body weight less than 50 kg, children from 6 to 12 years old, old age.
Use during pregnancy and lactation
Gastal ® is not excreted in breast milk. When used during pregnancy and during breastfeeding, it is necessary to assess the ratio of benefits for the mother and risk for the fetus and baby.
Composition
1 tablet contains: active substances: aluminum hydroxide-magnesium carbonate gel 450.0 mg, magnesium hydroxide 300.0 mg excipients: lactose monohydrate 111.5 / 112.0 / 112.0 mg, mannitol 110.0 / 112.0 / 112.0 mg, Pregelatinized starch 32.0 / 32.0 / 32.0 mg, colloidal silicon dioxide 2.0 / 2.0 / 2.0 mg, croscarmellose sodium (type A) 50.0 / 50.0 / 50.0 mg, aspartame 2.5 / 2.0 / 2.0 mg, magnesium stearate 6.0 / 6.0 / 6.0 mg, mint flavor 11890-71 (mint tablets) 6.0 mg or cherry flavor E 9407963 (cherry tablets ) 4.0 mg or orange flavor 1013042 (orange tablets) 4.0 mg.
Dosage and administration
Inside, gradually dissolving in the mouth.
Adults and children over 12 years old with a body weight of at least 50 kg
1-2 tablets 4-6 times a day, approximately 1 hour after eating and at bedtime, but not more than 8 tablets per day. Duration of admission is no more than 2 weeks.
Similar doses are recommended for treating heartburn regardless of food intake.
Adults and children over 12 years old with a body weight of less than 50 kg, children aged 6 to 12 years
The dose is half the recommended dose for adults and children over 12 years of age with a body weight of at least 50 kg. Duration of admission is no more than 2 weeks.
Patients with chronic renal failure
Dose adjustment not required. Duration of admission is no more than 2 weeks.
Side effects
When using the drug in recommended doses, adverse reactions are rare (not less than 0.01%, but less than 0.1%): nausea, constipation, diarrhea, a change in taste. In exceptional cases, allergic reactions are possible.
Drug interaction
Gastal ® preparation at the same time enhances the activity of levodopa and nalidoxin indirect anticoagulants, barbiturates.
When interacting with metal ions that are part of antacids, tetracyclines form insoluble chelate complexes as a result of this interaction, the absorption of tetracyclines is reduced by more than 90%. Simultaneous administration of these drugs is impossible. When combined, tetracycline should be taken at least 2 hours before the antacid is taken.
In the presence of the aluminum and magnesium hydroxides contained in the antacid, the absorption of ciprofloxacin and ofloxacin is reduced by 50-90%.
In the presence of antacids, the bioavailability of captopril is significantly reduced, and the combined use of antacids and metoprolol leads to a decrease in the plasma metoprolol concentration.
Concomitant use of high doses of antacids can reduce ranitidine absorption by 10-33%.
The use of antacids does not affect the bioavailability of amoxicillin, cephalexin and combinations of amoxicillin and clavulanic acid, however, can significantly reduce the absorption of doxycycline from the gastrointestinal tract.
Increasing the urine pH against antacid therapy can help to increase tubular reabsorption of essential (alkaline) drugs and reduce reabsorption of acidic compounds. Antacids can reduce and slow the absorption of salicylates, including acetylsalicylic acid, and, by increasing the urine pH, promote faster elimination of salicylates with urine from the body, with a concomitant decrease in their serum concentration by 30-70%.
The absorption of cardiac glycosides, including digoxin and digitoxin, is not significantly reduced when used with antacids.
M-cholin blockers, by slowing the motility of the stomach, increase the duration of the drug Gastal ®.
In order to prevent the possible interaction of Gastal ® with other drugs, it is recommended that it be administered 1 hour before or 1 hour after use.
Overdose
Symptoms of acute overdose are not described.
With prolonged use of high doses of preparations containing aluminum and magnesium, the development of hypophosphatemia, hypocalcemia, hypercalciuria, osteomalacia, osteoporosis, hypermagnesemia, hyperaluminiemia, encephalopathy, nephrocalculia, may develop. It is possible to develop more pronounced undesirable reactions from the gastrointestinal tract (gastrointestinal tract) (constipation, diarrhea), in patients with renal insufficiency – thirst, a decrease in blood pressure, and hyporeflexia.
Treatment: symptomatic therapy.
Storage conditions
Store at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf suitability
3 Year
active ve
hydrotalcite, magnesium hydroxide
Dispensing conditions from
pharmacies No prescription
Formulation
Formulation
lozenges
Teva Pharmaceutical Enterprise Co., Ltd., Israel
